SKYRIZI: An IL-23/p19 inhibitor2-7
IMMerge H2H data
HEAD-TO-HEAD DATA:
SKYRIZI DEMONSTRATED SUPERIORITY
vs secukinumab at Week 52 (NRI) in a Phase 3b PsO study26,27
DURABLE CLEARANCE:
PASI 90 AT WEEK 5226,27
DURABLE, COMPLETE CLEARANCE:
PASI 100 AT WEEK 5226,27
| PASI 90 and PASI 100 data are computed using NRI. | |
| * | SKYRIZI doses denoted in blue: Participants received 150 mg SKYRIZI at Week 0, Week 4, and every 12 weeks thereafter.1 |
| † | Secukinumab is dosed 300 mg at Week 0, Week 1, Week 2, Week 3, Week 4, and every 4 weeks thereafter. |
| ‡ | P=0.039 |
| § | P<0.001 vs secukinumab. |
| || | 30% absolute difference in patients achieving PASI 90 at Week 52 with SKYRIZI (95% CI: adjusted difference; 20.8, 38.8).26,27 |
| ¶ | 26% absolute difference in patients achieving PASI 100 at Week 52 with SKYRIZI (95% CI: adjusted difference; 15.9, 36.5).26,27 |
Watch time: 5:41 min.
See Professor Warren give his perspective on the IMMerge PsO study
Posted 09/25/20
IMMerge study design26,27
SKYRIZI vs secukinumab assessor-blinded, head-to-head trial
A Phase 3b, multicenter, randomized, open-label, efficacy assessor-blinded, active-comparator study designed to evaluate the safety and efficacy of SKYRIZI compared to secukinumab in adult patients with moderate to severe plaque psoriasis.
Primary endpoints were PASI 90 at Week 52 (superiority) and PASI 90 at Week 16 (noninferiority).
You may also be interested in
